These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 33861486)

  • 1. Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II Study.
    Nebhan CA; Johnson DB; Sullivan RJ; Amaria RN; Flaherty KT; Sosman JA; Davies MA
    Oncologist; 2021 Sep; 26(9):731-e1498. PubMed ID: 33861486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma.
    Si L; Zhang X; Shin SJ; Fan Y; Lin CC; Kim TM; Dechaphunkul A; Maneechavakajorn J; Wong CS; Ilankumaran P; Lee DY; Gasal E; Li H; Guo J
    Eur J Cancer; 2020 Aug; 135():31-38. PubMed ID: 32534242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
    Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
    JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600-mutant advanced melanoma.
    Kim CG; Kim M; Hwang J; Kim ST; Jung M; Kim KH; Kim KH; Chang JS; Koom WS; Roh MR; Chung KY; Kim TM; Kim SK; Lee J; Shin SJ
    J Am Acad Dermatol; 2022 Nov; 87(5):989-996. PubMed ID: 36068115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF
    Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B
    Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dabrafenib plus trametinib in patients with BRAF
    Davies MA; Saiag P; Robert C; Grob JJ; Flaherty KT; Arance A; Chiarion-Sileni V; Thomas L; Lesimple T; Mortier L; Moschos SJ; Hogg D; Márquez-Rodas I; Del Vecchio M; Lebbé C; Meyer N; Zhang Y; Huang Y; Mookerjee B; Long GV
    Lancet Oncol; 2017 Jul; 18(7):863-873. PubMed ID: 28592387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i.
    Dummer R; Lebbé C; Atkinson V; Mandalà M; Nathan PD; Arance A; Richtig E; Yamazaki N; Robert C; Schadendorf D; Tawbi HA; Ascierto PA; Ribas A; Flaherty KT; Pakhle N; Campbell CD; Gusenleitner D; Masood A; Brase JC; Gasal E; Long GV
    Nat Med; 2020 Oct; 26(10):1557-1563. PubMed ID: 33020648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
    Long GV; Flaherty KT; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Chiarion-Sileni V; Lebbe C; Mandalà M; Millward M; Arance A; Bondarenko I; Haanen JBAG; Hansson J; Utikal J; Ferraresi V; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; Davies MA; Lane SR; Legos JJ; Mookerjee B; Grob JJ
    Ann Oncol; 2017 Jul; 28(7):1631-1639. PubMed ID: 28475671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced cutaneous melanoma.
    Yamazaki N; Tsutsumida A; Takahashi A; Namikawa K; Yoshikawa S; Fujiwara Y; Kondo S; Mukaiyama A; Zhang F; Kiyohara Y
    J Dermatol; 2018 Apr; 45(4):397-407. PubMed ID: 29399853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.
    Johnson DB; Flaherty KT; Weber JS; Infante JR; Kim KB; Kefford RF; Hamid O; Schuchter L; Cebon J; Sharfman WH; McWilliams RR; Sznol M; Lawrence DP; Gibney GT; Burris HA; Falchook GS; Algazi A; Lewis K; Long GV; Patel K; Ibrahim N; Sun P; Little S; Cunningham E; Sosman JA; Daud A; Gonzalez R
    J Clin Oncol; 2014 Nov; 32(33):3697-704. PubMed ID: 25287827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
    Flaherty KT; Infante JR; Daud A; Gonzalez R; Kefford RF; Sosman J; Hamid O; Schuchter L; Cebon J; Ibrahim N; Kudchadkar R; Burris HA; Falchook G; Algazi A; Lewis K; Long GV; Puzanov I; Lebowitz P; Singh A; Little S; Sun P; Allred A; Ouellet D; Kim KB; Patel K; Weber J
    N Engl J Med; 2012 Nov; 367(18):1694-703. PubMed ID: 23020132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma.
    Robert C; Flaherty K; Nathan P; Hersey P; Garbe C; Milhem M; Demidov L; Mohr P; Hassel JC; Rutkowski P; Dummer R; Utikal J; Kiecker F; Larkin J; D'Amelio A; Mookerjee B; Schadendorf D
    Eur J Cancer; 2019 Mar; 109():61-69. PubMed ID: 30690294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAF
    Dayimu A; Gupta A; Matin RN; Nobes J; Board R; Payne M; Rao A; Fusi A; Danson S; Eccles B; Carser J; Brown CO; Steven N; Bhattacharyya M; Brown E; Gonzalez M; Highley M; Pickering L; Kumar S; Waterston A; Burghel G; Demain L; Baker E; Wulff J; Qian W; Twelves S; Middleton M; Corrie P
    Eur J Cancer; 2024 Jan; 196():113455. PubMed ID: 38029480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib.
    Saiag P; Robert C; Grob JJ; Mortier L; Dereure O; Lebbe C; Mansard S; Grange F; Neidhardt EM; Lesimple T; Machet L; Bedane C; Maillard H; Dalac-Rat S; Nardin C; Szenik A; Denden A; Dutriaux C
    Eur J Cancer; 2021 Sep; 154():57-65. PubMed ID: 34243078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
    Long GV; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Schadendorf D; Lesimple T; Plummer R; Ji R; Zhang P; Mookerjee B; Legos J; Kefford R; Dummer R; Kirkwood JM
    N Engl J Med; 2017 Nov; 377(19):1813-1823. PubMed ID: 28891408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
    Menzies AM; Long GV
    Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trametinib (MEKINIST°) Metastatic or inoperable BRAF V600-positive melanoma: a few extra months of life.
    Prescrire Int; 2016 Dec; 25(177):285-288. PubMed ID: 30758923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II).
    Atkinson V; Sandhu S; Hospers G; Long GV; Aglietta M; Ferrucci PF; Tulyte S; Cappellini GCA; Soriano V; Ali S; Poprach A; Cesas A; Rodriguez-Abreu D; Lau M; de Jong E; Legenne P; Stein D; King B; van Thienen JV
    Melanoma Res; 2020 Jun; 30(3):261-267. PubMed ID: 31895752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for
    Dummer R; Long GV; Robert C; Tawbi HA; Flaherty KT; Ascierto PA; Nathan PD; Rutkowski P; Leonov O; Dutriaux C; Mandalà M; Lorigan P; Ferrucci PF; Grob JJ; Meyer N; Gogas H; Stroyakovskiy D; Arance A; Brase JC; Green S; Haas T; Masood A; Gasal E; Ribas A; Schadendorf D
    J Clin Oncol; 2022 May; 40(13):1428-1438. PubMed ID: 35030011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.